07:00 , Jul 29, 2013 |  BC Week In Review  |  Company News

Biovest cancer, biomanufacturing news

Biovest emerged from Chapter 11 bankruptcy and completed a restructuring and recapitalization strategy. The company has eliminated about $48.5 million in debt, which has been converted into new shares of Biovest common stock and issued...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Company News

Biovest cancer news

Biovest filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Middle District of Florida. Biovest is seeking access to up to about $5.6 million in new funding from its senior secured lenders....
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer  A strong crop of early PDUFA dates and a sense that...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Clinical News

BiovaxID regulatory update

Accentia's Biovest International Inc. (OTCQB:BTVI, Tampa Fla.) subsidiary said FDA requested a second Phase III trial to support a BLA submission for BiovaxID as consolidation therapy in follicular non-Hodgkin's lymphoma (NHL). The agency requested the...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

BiovaxID regulatory update

Accentia's Biovest International Inc. (OTCQB:BTVI, Tampa Fla.) subsidiary said EMA formally notified the subsidiary that an MAA for BiovaxID to treat follicular non-Hodgkin's lymphoma (NHL) is eligible for review under EMA's centralized procedure. Biovest plans...
07:00 , Jul 2, 2012 |  BioCentury  |  Finance

3Q Financial Markets Preview: Miles of milestones

A deep line-up of milestones could help retain gains the sector has been holding onto since 1Q12. In particular, investors would love to see further breakthroughs in difficult areas such as Alzheimer's disease and obesity....
07:00 , Jun 18, 2012 |  BioCentury  |  Product Development

Immune springboard

A spate of Phase III data events over the next two years will give a readout on how correctly the lessons learned five years ago about cancer immunotherapies targeting T cell responses have been put...
07:00 , Jun 4, 2012 |  BC Week In Review  |  Clinical News

BiovaxID: Additional Phase II data

Accentia's Biovest International Inc. (OTCQB:BTVI, Tampa Fla.) subsidiary reported additional data from a Phase II trial in 26 treatment-naïve patients with MCL showing that BiovaxID led to median progression-free survival (PFS) of 24 months and...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Company News

Biovest, USAMRIID biomanufacturing news

Biovest signed a CRADA with the institute to develop Biovest's hollow fiber perfusion bioreactors for flexible, modular manufacturing of medical countermeasures. The CRADA will use Biovest's hollow fiber technology for production of vaccines, virus-like particles...
08:00 , Jan 23, 2012 |  BC Week In Review  |  Company News

Accentia, The Max Planck Society for the Advancement of Science deal

Accentia's Biovest International Inc. (OTCQB:BVTI, Tampa, Fla.) subsidiary and Max Planck's Max Plank Institute for Dynamics of Complex Technical Systems partnered to evaluate Biovest's Hollow Fiber Bioreactor Systems to manufacture influenza vaccines. The Max Plank...